The whole library, viewed from above
Computed overviews of all 89 compounds — what is evidenced, what is only discussed, and where those two things disagree. Every figure is derived from the monographs at page load, so nothing here can go stale.
Discussion vs evidence
Every compound plotted by how much it is talked about against how well it is supported, with the widest gaps named.
All peptides, rated
The full reference: mechanism, regulatory status, benefits and risks, each graded on the strength of the evidence.
Every term, defined
The vocabulary of peptide pharmacology and trial design, in plain language and cross-linked throughout the site.
Two compounds, side by side
Direct comparisons on evidence, status, benefits and risks — for the pairs people actually weigh against each other.
How we rate evidence
The fixed 1-5 scale, what each level requires, and why a rating never moves because a compound sounds promising.
Risks that cross every compound
Product quality, sterility, growth signalling and interactions — the hazards that do not belong to any single monograph.